Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Autoimmune Disorders

Free Subscription Articles published in Lancet Retrieve available abstracts of 45 articles: HTML format Text format

Single Articles

March 2019
1. COSTACOU T, Guo J, Miller RG, Orchard TJ, et al
   Excess mortality and cardiovascular disease risk in type 1 diabetes.
   Lancet. 2019;393:985.
   PubMed     Text format    
   
   
   
2. RAWSHANI A, Sattar N, Franzen S, Rawshani A, et al
   Excess mortality and cardiovascular disease risk in type 1 diabetes - Authors' reply.
   Lancet. 2019;393:985-986.
   PubMed     Text format    
   
   
   
3. SNAITH JR, Holmes-Walker DJ, Girgis CM, Greenfield JR, et al
   Excess mortality and cardiovascular disease risk in type 1 diabetes.
   Lancet. 2019;393:984-985.
   PubMed     Text format    
   
   
   February 2019
4. YUAN K, Huang G, Sang X, Xu A, et al
   Baricitinib for systemic lupus erythematosus.
   Lancet. 2019;393:402.
   PubMed     Text format    
   
   
   
5. WALLACE DJ, Furie RA, Tanaka Y, de Bono S, et al
   Baricitinib for systemic lupus erythematosus - Authors' reply.
   Lancet. 2019;393:402-403.
   PubMed     Text format    
   
   
   January 2019
6. POWER SP, O'Mahony D
   Diffuse large vessel giant cell arteritis found by (18)Fluorodeoxyglucose PET/CT imaging.
   Lancet. 2019;393:349.
   PubMed     Text format    
   
   
   December 2018
7. THE LANCET
   Type 2 diabetes: the urgent need to protect young people.
   Lancet. 2018;392:2325.
   PubMed     Text format    
   
   
   October 2018
8. COSTEDOAT-CHALUMEAU N, Houssiau FA
   Ustekinumab: a promising new drug for SLE?
   Lancet. 2018;392:1284-1286.
   PubMed     Text format    
   
   
   
9. GALDERISI A, Sherr JL
   Enlarging the loop: closed-loop insulin delivery for type 1 diabetes.
   Lancet. 2018 Oct 1. pii: S0140-6736(18)32329.
   PubMed     Text format    
   
   
   
10. TAUSCHMANN M, Thabit H, Bally L, Allen JM, et al
    Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial.
    Lancet. 2018 Oct 1. pii: S0140-6736(18)31947.
    PubMed     Text format     Abstract available
    
    
    September 2018
11. VAN VOLLENHOVEN RF, Hahn BH, Tsokos GC, Wagner CL, et al
    Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study.
    Lancet. 2018 Sep 21. pii: S0140-6736(18)32167.
    PubMed     Text format     Abstract available
    
    
    
12. LEBWOHL B, Sanders DS, Green PH
    Coeliac disease and dermatitis herpetiformis - Authors' reply.
    Lancet. 2018;392:917.
    PubMed     Text format    
    
    
    
13. RODRIGUES F, Bachmeyer C
    Coeliac disease and dermatitis herpetiformis.
    Lancet. 2018;392:916.
    PubMed     Text format    
    
    
    
14. CAIO G, De Giorgio R, Volta U
    Coeliac disease and dermatitis herpetiformis.
    Lancet. 2018;392:916-917.
    PubMed     Text format    
    
    
    
15. FLUME PA, Chalmers JD, Olivier KN
    Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity.
    Lancet. 2018;392:880-890.
    PubMed     Text format     Abstract available
    
    
    
16. PERL A, Lai ZW, Kelly R, Faraone SV, et al
    Sirolimus for systemic lupus erythematosus - Authors' reply.
    Lancet. 2018;392:734.
    PubMed     Text format    
    
    
    
17. HU HQ, Lee FJ, Garsia R
    Sirolimus for systemic lupus erythematosus.
    Lancet. 2018;392:733-734.
    PubMed     Text format    
    
    
    August 2018
18. BASINA M, Maahs DM
    Age at type 1 diabetes onset: a new risk factor and call for focused treatment.
    Lancet. 2018;392:453-454.
    PubMed     Text format    
    
    
    
19. RAWSHANI A, Sattar N, Franzen S, Rawshani A, et al
    Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study.
    Lancet. 2018;392:477-486.
    PubMed     Text format     Abstract available
    
    
    July 2018
20. WALLACE DJ, Furie RA, Tanaka Y, Kalunian KC, et al
    Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.
    Lancet. 2018;392:222-231.
    PubMed     Text format     Abstract available
    
    
    
21. MUCKE J, Schneider M
    Baricitinib for systemic lupus erythematosus.
    Lancet. 2018;392:190-192.
    PubMed     Text format    
    
    
    June 2018
22. XIAO F, Tian X, Wang XF
    Antiphospholipid syndrome causing reversible internal carotid artery thrombosis.
    Lancet. 2018;391:2641.
    PubMed     Text format    
    
    
    
23. DIMEGLIO LA, Evans-Molina C, Oram RA
    Type 1 diabetes.
    Lancet. 2018;391:2449-2462.
    PubMed     Text format     Abstract available
    
    
    March 2018
24. CHATTERJEE S, Khunti K, Davies MJ
    Type 2 diabetes - Authors' reply.
    Lancet. 2018;391:1262.
    PubMed     Text format    
    
    
    
25. TATE AR
    Type 2 diabetes.
    Lancet. 2018;391:1261-1262.
    PubMed     Text format    
    
    
    
26. BOUSSAGEON R, Roustit M, Gueyffier F, Tudrej BV, et al
    Type 2 diabetes.
    Lancet. 2018;391:1261.
    PubMed     Text format    
    
    
    
27. METZ LM, Liu WQ
    Effective treatment of progressive MS remains elusive.
    Lancet. 2018;391:1239-1240.
    PubMed     Text format    
    
    
    
28. KAPPOS L, Bar-Or A, Cree BAC, Fox RJ, et al
    Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.
    Lancet. 2018 Mar 22. pii: S0140-6736(18)30475.
    PubMed     Text format     Abstract available
    
    
    
29. THOMPSON AJ, Baranzini SE, Geurts J, Hemmer B, et al
    Multiple sclerosis.
    Lancet. 2018 Mar 22. pii: S0140-6736(18)30481.
    PubMed     Text format     Abstract available
    
    
    
30. THE LANCET
    End of the road for daclizumab in multiple sclerosis.
    Lancet. 2018;391:1000.
    PubMed     Text format    
    
    
    
31. LAI ZW, Kelly R, Winans T, Marchena I, et al
    Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial.
    Lancet. 2018 Mar 15. pii: S0140-6736(18)30485.
    PubMed     Text format     Abstract available
    
    
    
32. FERNANDEZ DR, Crow MK
    CD8 T cells and mTOR: new concepts and targets for systemic lupus erythematous.
    Lancet. 2018 Mar 15. pii: S0140-6736(18)30544.
    PubMed     Text format    
    
    
    February 2018
33. BERGENSTAL RM
    Continuous glucose monitoring: transforming diabetes management step by step.
    Lancet. 2018 Feb 15. pii: S0140-6736(18)30290.
    PubMed     Text format    
    
    
    
34. HEINEMANN L, Freckmann G, Ehrmann D, Faber-Heinemann G, et al
    Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial.
    Lancet. 2018 Feb 15. pii: S0140-6736(18)30297.
    PubMed     Text format     Abstract available
    
    
    January 2018
35. BARNETT R
    Type 1 diabetes.
    Lancet. 2018;391:195.
    PubMed     Text format    
    
    
    December 2017
36. TSUDA K, Tanimoto T, Mori J, Kosugi K, et al
    Targeted-release budesonide therapy for IgA nephropathy.
    Lancet. 2017;390:2625.
    PubMed     Text format    
    
    
    
37. FELLSTROM B, Barratt J, Floge J, Jardine A, et al
    Targeted-release budesonide therapy for IgA nephropathy - Authors' reply.
    Lancet. 2017;390:2625-2626.
    PubMed     Text format    
    
    
    October 2017
38. GREEN AJ, Gelfand JM, Cree BA, Bevan C, et al
    Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial.
    Lancet. 2017 Oct 10. pii: S0140-6736(17)32346.
    PubMed     Text format     Abstract available
    
    
    
39. RUBIN R
    Mary Crow: leader in research on systemic lupus erythematosus.
    Lancet. 2017;390:1636.
    PubMed     Text format    
    
    
    September 2017
40. GARG SK, Polsky S
    Continuous glucose monitoring in pregnant women with type 1 diabetes.
    Lancet. 2017 Sep 14. pii: S0140-6736(17)32449.
    PubMed     Text format    
    
    
    
41. FEIG DS, Donovan LE, Corcoy R, Murphy KE, et al
    Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial.
    Lancet. 2017 Sep 14. pii: S0140-6736(17)32400.
    PubMed     Text format     Abstract available
    
    
    March 2017
42. WYATT RJ
    Are we ready for targeted therapy for IgA nephropathy?
    Lancet. 2017 Mar 28. pii: S0140-6736(17)30820.
    PubMed     Text format    
    
    
    
43. FELLSTROM BC, Barratt J, Cook H, Coppo R, et al
    Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial.
    Lancet. 2017 Mar 28. pii: S0140-6736(17)30550.
    PubMed     Text format     Abstract available
    
    
    December 2016
44. EL-KHATIB FH, Balliro C, Hillard MA, Magyar KL, et al
    Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial.
    Lancet. 2016 Dec 20. pii: S0140-6736(16)32567.
    PubMed     Text format     Abstract available
    
    
    September 2016
45. BOLINDER J, Antuna R, Geelhoed-Duijvestijn P, Kroger J, et al
    Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial.
    Lancet. 2016 Sep 9. pii: S0140-6736(16)31535.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: